Viewing StudyNCT06424821



Ignite Creation Date: 2024-06-16 @ 11:48 AM
Last Modification Date: 2024-10-26 @ 3:30 PM
Study NCT ID: NCT06424821
Status: RECRUITING
Last Update Posted: 2024-05-22
First Post: 2024-05-12

Brief Title: Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC
Sponsor: Shanghai Pulmonary Hospital Shanghai China
Organization: Shanghai Pulmonary Hospital Shanghai China

Conditions & Keywords Data

Conditions:
Name
NSCLC
Keywords:
Name View
PD-1CTLA-4 bispecific antibody View
PD-L1 negative View